MX2022013148A - Nucleoproteina viral y formulaciones que la contienen. - Google Patents

Nucleoproteina viral y formulaciones que la contienen.

Info

Publication number
MX2022013148A
MX2022013148A MX2022013148A MX2022013148A MX2022013148A MX 2022013148 A MX2022013148 A MX 2022013148A MX 2022013148 A MX2022013148 A MX 2022013148A MX 2022013148 A MX2022013148 A MX 2022013148A MX 2022013148 A MX2022013148 A MX 2022013148A
Authority
MX
Mexico
Prior art keywords
nucleoprotein
rna
relates
infectious
mass
Prior art date
Application number
MX2022013148A
Other languages
English (en)
Inventor
Nieto Gerardo Enrique Guillen
Aguilar Rubido Julio César
Santiago Jorge Agustín Aguiar
Maarten Van-De-Klundert
Martin Kächele
Mohammad Fazle Akbar Sheikh
Mamun Al-Mahtab
Helal Uddin
Frank Thiele
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of MX2022013148A publication Critical patent/MX2022013148A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Nucleoproteína que comprende ácido ribonucleico (ARN) y una proteína de origen viral donde el contenido de ARN es mayor del 20% (masa:masa) y dicho ARN se encuentra protegido de la degradación dentro de una estructura semejante a virus, y donde dicha nucleoproteína activa simultáneamente los receptores de la inmunidad innata TLR3,TLR2, TLR7, TLR8 y TLR9. Uso de dicha nucleoproteína para la fabricación de medicamentos que potencian una respuesta anti-infecciosa, anti-tumoral o anti-alérgica, o para la activación y el entrenamiento de la inmunidad innata en la prevención o tratamiento de procesos infecciosos o alérgicos. Esta nucleoproteína se puede emplear en tratamientos combinados con otros fármacos. También se revela el uso de la nucleoproteína para la fabricación de un adyuvante o un carrier de antígenos vacunales, la formulación farmacéutica que comprende la nucleoproteína y un kit para su administración mucosal.
MX2022013148A 2020-04-20 2021-04-16 Nucleoproteina viral y formulaciones que la contienen. MX2022013148A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2020000028A CU20200028A7 (es) 2020-04-20 2020-04-20 Nucleoproteína viral y formulaciones que la contienen
PCT/CU2021/050002 WO2021213558A2 (es) 2020-04-20 2021-04-16 Nucleoproteina viral y formulaciones que la contienen

Publications (1)

Publication Number Publication Date
MX2022013148A true MX2022013148A (es) 2022-11-16

Family

ID=77338444

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013148A MX2022013148A (es) 2020-04-20 2021-04-16 Nucleoproteina viral y formulaciones que la contienen.

Country Status (5)

Country Link
JP (1) JP2023522118A (es)
CN (1) CN115697394A (es)
CU (1) CU20200028A7 (es)
MX (1) MX2022013148A (es)
WO (1) WO2021213558A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202204803D0 (en) * 2022-04-01 2022-05-18 Univ Manchester Virus-like particles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1450856B1 (en) * 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
EP1644034B1 (en) * 2003-07-10 2011-01-12 Cytos Biotechnology AG Composition for enhancing an immune response comprising packaged virus-like particles
EP2498815A4 (en) * 2009-11-09 2014-03-19 Nat Jewish Health VACCINE COMPOSITION
EA201892212A1 (ru) 2016-03-31 2019-03-29 Сентро Де Инхеньерия Хенетика И Биотекнолохия Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b

Also Published As

Publication number Publication date
CU20200028A7 (es) 2021-11-04
WO2021213558A3 (es) 2021-12-30
CN115697394A (zh) 2023-02-03
WO2021213558A2 (es) 2021-10-28
JP2023522118A (ja) 2023-05-26

Similar Documents

Publication Publication Date Title
ES2731899T3 (es) Composición de vacuna nasal contra la gripe
Skene et al. Saponin-adjuvanted particulate vaccines for clinical use
ES2943385T3 (es) Compuesto modificador de la respuesta inmunitaria lipidada y su uso médico
ES2562456T3 (es) Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
US8945590B2 (en) Enhancement of an immune response by administration of a cationic lipid-DNA complex (CLDC)
MX2022009018A (es) Nanoparticulas lipidas.
MX2022015690A (es) Nanoparticulas lipidicas.
CN103608036A (zh) 包含菊粉颗粒的免疫佐剂组合物
Schulze et al. New horizons in the development of novel needle-free immunization strategies to increase vaccination efficacy
MX2025010536A (es) Nuevas formulaciones de nanoparticulas lipidicas para la administracion de acidos nucleicos
WO2021213558A3 (es) Nucleoproteina viral y formulaciones que la contienen
JP5804278B2 (ja) 粘膜ワクチン
Kawai et al. Lipid nanoparticle with 1, 2-Di-O-octadecenyl-3-trimethylammonium-propane as a component lipid confers potent responses of Th1 cells and antibody against vaccine antigen
Aroffu et al. Liposome-based vaccines for minimally or noninvasive administration: an update on current advancements
JP7618632B2 (ja) 経鼻ｂ型肝炎ワクチン組成物およびその製造方法
KR102654379B1 (ko) 신규한 핵산을 기반으로 하는 인플루엔자 백신 조성물
Liu et al. Polymeric nanoparticles engineered as a vaccine adjuvant-delivery system
WO2004016281A1 (en) Intradermal influenza vaccine compositions containing an adp-ribosylating factor
JP2010508308A (ja) 鳥インフルエンザウイルス感染の予防的治療のためのポリｉｃｌｃカプセル化リポソーム
Tomai et al. Toll-like receptor 7 and 8 agonists for vaccine adjuvant use
CN101754770B (zh) 皮内流感疫苗
EP3017040B1 (en) Method for preparing virosomes
Baig et al. From Viral Vaccines to Messenger RNA Vaccines
US20220280631A1 (en) Viral pandemic vaccine
HK40007838A (en) Nasal influenza vaccine composition